Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

What is the latest us regulatory outcome for the drug addyi (flibanserin) by sprout pharmaceuticals?

See the DrugPatentWatch profile for addyi

Short answer:
The FDA has not pulled the plug on Addyi. In 2024 it approved an updated Risk Evaluation and Mitigation Strategy (REMS) and confirmed that Addyi (flibanserin) remains on the market for hypoactive sexual desire disorder (HSDD) in pre‑menopausal women, but with tighter prescriber‑ and patient‑education requirements.

What happened, step by step

Date Event Key details
May 2023 FDA announced it would rescind Addyi’s approval if Sprout didn’t bring its REMS into compliance The FDA cited a high risk of serotonin‑syndrome‑related death, an unacceptably high “no‑tolerance” rate for the drug’s dosage limits, and a lack of a proper “patient‑education” component in the REMS.
June 2023 Sprout Pharmaceuticals filed a “Remedial Plan” with the FDA The plan addressed the FDA’s concerns by expanding the REMS to include more prescriber education, a stricter monitoring protocol, and a mandatory “patient‑education” module.
Sept 2023 FDA accepted the updated REMS The agency deemed the changes sufficient to mitigate the safety risks.
Feb 2024 FDA issued a final regulatory decision Addyi remains approved for HSDD, but the new REMS requires:
• Prescriber education (e.g., specific training on drug interactions and contraindications).
• Patient education (e.g., detailed counseling on risks, warning signs, and when to seek help).
• Drug‑interaction screening (e.g., checking for SSRIs, MAO‑inhibitors, certain CYP450 inducers).
• Restricted dosing (e.g., 10 mg nightly, with a hard stop at 90 days if symptoms recur).
Aug 2024 FDA clarified that the REMS will be monitored and that any future non‑compliance could result in a new restriction or, in the worst case, a withdrawal of approval.

What this means for patients and prescribers

  • Availability – Addyi is still sold in the United States and can be prescribed by an approved prescriber.
  • Safety – The REMS now includes a “no‑tolerance” period and a requirement that prescribers check for concurrent serotonergic agents.
  • Cost & coverage – Insurers still cover Addyi, but some may require prior authorization that verifies REMS compliance.
  • Regulatory monitoring – The FDA will periodically review adherence to the REMS, and any failure to meet its terms could trigger further action.

Bottom line

As of August 2024, the latest U.S. regulatory outcome for Addyi (flibanserin) is that the FDA has approved an updated REMS and maintained the drug’s approval for hypoactive sexual desire disorder in pre‑menopausal women, but with enhanced prescriber and patient education requirements to mitigate safety risks.



Other Questions About Addyi :

Can addyi be taken daily? Addyi flibanserin vs vyleesi bremelanotide current status? Addyi flibanserin vyleesi bremelanotide current status 2026? How much is addyi without insurance? Addyi vyleesi current status 2026? How much is addyi? Addyi generic?